These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 15374938)
1. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Krysan K; Dalwadi H; Sharma S; Põld M; Dubinett S Cancer Res; 2004 Sep; 64(18):6359-62. PubMed ID: 15374938 [TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387 [TBL] [Abstract][Full Text] [Related]
3. COX-2-dependent stabilization of survivin in non-small cell lung cancer. Krysan K; Merchant FH; Zhu L; Dohadwala M; Luo J; Lin Y; Heuze-Vourc'h N; Põld M; Seligson D; Chia D; Goodglick L; Wang H; Strieter R; Sharma S; Dubinett S FASEB J; 2004 Jan; 18(1):206-8. PubMed ID: 14597555 [TBL] [Abstract][Full Text] [Related]
4. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Chen W; Wang X; Zhuang J; Zhang L; Lin Y Carcinogenesis; 2007 Oct; 28(10):2114-21. PubMed ID: 17548900 [TBL] [Abstract][Full Text] [Related]
5. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Huang M; Stolina M; Sharma S; Mao JT; Zhu L; Miller PW; Wollman J; Herschman H; Dubinett SM Cancer Res; 1998 Mar; 58(6):1208-16. PubMed ID: 9515807 [TBL] [Abstract][Full Text] [Related]
6. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Jin Q; Feng L; Behrens C; Bekele BN; Wistuba II; Hong WK; Lee HY Cancer Res; 2007 Dec; 67(24):11630-9. PubMed ID: 18089792 [TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Põld M; Krysan K; Põld A; Dohadwala M; Heuze-Vourc'h N; Mao JT; Riedl KL; Sharma S; Dubinett SM Cancer Res; 2004 Sep; 64(18):6549-55. PubMed ID: 15374967 [TBL] [Abstract][Full Text] [Related]
8. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Tanabe H; Yagihashi A; Tsuji N; Shijubo Y; Abe S; Watanabe N Lung Cancer; 2004 Dec; 46(3):299-304. PubMed ID: 15541814 [TBL] [Abstract][Full Text] [Related]
9. Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer. Cui X; Zhang L; Luo J; Rajasekaran A; Hazra S; Cacalano N; Dubinett SM Oncogene; 2007 Jun; 26(29):4253-60. PubMed ID: 17237818 [TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429 [TBL] [Abstract][Full Text] [Related]
11. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Huang CL; Liu D; Nakano J; Yokomise H; Ueno M; Kadota K; Wada H Clin Cancer Res; 2007 Dec; 13(23):6938-46. PubMed ID: 18056168 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Ermert L; Dierkes C; Ermert M Clin Cancer Res; 2003 May; 9(5):1604-10. PubMed ID: 12738712 [TBL] [Abstract][Full Text] [Related]
13. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. Nakano J; Huang CL; Liu D; Ueno M; Sumitomo S; Yokomise H Int J Oncol; 2005 Nov; 27(5):1215-21. PubMed ID: 16211215 [TBL] [Abstract][Full Text] [Related]
14. Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells. Heuze-Vourc'h N; Zhu L; Krysan K; Batra RK; Sharma S; Dubinett SM Cancer Res; 2003 Feb; 63(4):766-70. PubMed ID: 12591723 [TBL] [Abstract][Full Text] [Related]
15. Up-regulation of survivin mRNA might be a marker for non-invasive detection of non-small cell lung cancer rather than for prognosis. Warnecke-Eberz U; Baldus SE; Bollschweiler E; Hoelscher AH; Metzger R Anticancer Res; 2008; 28(3A):1525-9. PubMed ID: 18630507 [TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Krysan K; Reckamp KL; Dalwadi H; Sharma S; Rozengurt E; Dohadwala M; Dubinett SM Cancer Res; 2005 Jul; 65(14):6275-81. PubMed ID: 16024629 [TBL] [Abstract][Full Text] [Related]
17. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223 [TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Rahman KW; Li Y; Wang Z; Sarkar SH; Sarkar FH Cancer Res; 2006 May; 66(9):4952-60. PubMed ID: 16651453 [TBL] [Abstract][Full Text] [Related]
19. Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. Hofmann HS; Simm A; Hammer A; Silber RE; Bartling B J Cancer Res Clin Oncol; 2002 Oct; 128(10):554-60. PubMed ID: 12384799 [TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Hida T; Kozaki K; Muramatsu H; Masuda A; Shimizu S; Mitsudomi T; Sugiura T; Ogawa M; Takahashi T Clin Cancer Res; 2000 May; 6(5):2006-11. PubMed ID: 10815926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]